Business
GERON CORP: Additionally, we plan to execute on our pipeline programs and assess the data to understand the potential to develop imetelstat in additional hematologic malignancies and as a potential combination therapy.
Net income increased 52.2% to ($83.5M), while Operating cash flow increased 49.2% to ($111.0M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($83.5M)Watch
- Cash generation — Free cash flow N/ANote
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 1 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as GERON CORP reports it. History and quarterly detail are in the app.
- Revenues Before Adjustments$223.1M
- Product revenues, net$183.6M
- Royalties$300K
Leadership changes
From GERON CORP's own filings, the day they're filed.
- Potential Payments Upon Termination · departureeff. 2025-10-16
- Related Narrative Disclosure · departureeff. 2025-10-16
- Harout Semerjian · President · appointmenteff. 2025-08-07
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-05-27
- 10-Q · Quarterly report2026-05-06
- DEF 14A · Annual proxy (pay & governance)2026-04-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about GERON CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.